Benchmark Issues Positive Forecast for NeoGenomics (NASDAQ:NEO) Stock Price

Posted by Geri Gentry on Jul 24th, 2026

NeoGenomics (NASDAQ:NEO – Get Free Report) had its price objective lifted by stock analysts at Benchmark from $11.00 to $16.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Benchmark’s price objective indicates a potential upside of 12.36% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen raised NeoGenomics from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. TD Cowen reissued a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Leerink Partners raised shares of NeoGenomics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $12.00 to $25.00 in a research note on Wednesday, April 29th. Finally, Weiss Ratings upgraded shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $14.57.

View Our Latest Analysis on NeoGenomics

NeoGenomics Price Performance

Shares of NASDAQ NEO opened at $14.24 on Friday. The company has a current ratio of 4.42, a quick ratio of 4.06 and a debt-to-equity ratio of 0.41. The firm has a market cap of $1.85 billion, a PE ratio of -18.49 and a beta of 1.74. NeoGenomics has a 1-year low of $4.72 and a 1-year high of $15.57. The company has a fifty day moving average price of $12.08 and a 200 day moving average price of $10.63.

NeoGenomics (NASDAQ:NEO – Get Free Report) last issued its quarterly earnings results on Tuesday, April 28th. The medical research company reported $0.01 EPS for the quarter, meeting the consensus estimate of $0.01. The firm had revenue of $186.67 million during the quarter, compared to analysts’ expectations of $184.54 million. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. Research analysts predict that NeoGenomics will post -0.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In other NeoGenomics news, Director Lynn A. Tetrault sold 5,307 shares of the stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total value of $59,916.03. Following the transaction, the director owned 91,422 shares in the company, valued at approximately $1,032,154.38. This represents a 5.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.10% of the stock is owned by insiders.

Hedge Funds Weigh In On NeoGenomics

Large investors have recently added to or reduced their stakes in the business. First Horizon Corp raised its stake in shares of NeoGenomics by 52.6% in the fourth quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock worth $30,000 after purchasing an additional 865 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of NeoGenomics during the second quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd boosted its position in shares of NeoGenomics by 110.2% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock valued at $35,000 after buying an additional 1,556 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in NeoGenomics during the fourth quarter worth $39,000. Finally, GAMMA Investing LLC grew its holdings in NeoGenomics by 68.2% during the fourth quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock worth $42,000 after buying an additional 1,460 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Company Profile

(Get Free Report)

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.